Clinical Trials Logo

Agoraphobia clinical trials

View clinical trials related to Agoraphobia.

Filter by:

NCT ID: NCT04793828 Recruiting - Clinical trials for Generalized Anxiety Disorder

A Transdiagnostic, Self-guided Internet Intervention ("Velibra") for Waitlist Patients With Anxiety Disorders

Start date: June 4, 2020
Phase: N/A
Study type: Interventional

The project's aim is to investigate the effect of a transdiagnostic, self-guided, internet-based cognitive behavioral therapy program in waitlist patients with anxiety disorders.

NCT ID: NCT04695249 Active, not recruiting - Clinical trials for Social Anxiety Disorder

Using 360° Videos in the Treatment of Anxiety Disorders

Start date: January 4, 2021
Phase: N/A
Study type: Interventional

This study aims to test the feasibility and efficacy of an individualized exposure intervention using 360-degree videos for social anxiety and agoraphobia. A multiple single case design is followed with a pre-post-follow up assessment and multiple baselines. In addition, an experience sampling method is used to explore the role of dysfunctional beliefs and self-efficacy in the efficacy intervention.

NCT ID: NCT04681261 Completed - Covid19 Clinical Trials

Occupational Balance, Fear and Agoraphobia

OB
Start date: May 4, 2020
Phase:
Study type: Observational

This study was planned to investigate occupational balance, fear of Covid-19 and agoraphobia in adults during the Covid-19 pandemic.

NCT ID: NCT04569760 Withdrawn - Clinical trials for Generalized Anxiety Disorder

Cannabinoids for the Treatment of Anxiety Disorders: An 8-Week Pilot Study

Start date: April 2021
Phase: Phase 3
Study type: Interventional

This proposed study aims to evaluate the efficacy of a daily oral cannabinoid oil preparation in treating symptoms of DSM-5 anxiety disorders, using a two-arm, 8-week randomized, placebo-controlled trial in adults aged 21-65 years. The study will also evaluate the relationship between inflammation, anxiety and cannabinoids using biological markers as well as examine the neuro-cognitive effects of cannabinoid treatment.

NCT ID: NCT04568109 Completed - Clinical trials for Panic Disorder With Agoraphobia

Effect of Cognitive-behavior Therapy on Fear Responses to Body Symptoms in Patients With Panic Disorder

Start date: February 1, 2010
Phase: N/A
Study type: Interventional

The present study aims to investigate a potential mechanism of successful CBT for panic disorder, i.e., the reduction of excessive anxious apprehension and fear responses to panic-related body symptoms in the context of CBT treatment. In the present non-randomized interventional study, effects of cognitive behavior therapy on reported symptoms and fear responses to panic-related body symptoms are investigated. It is expected that symptom improvement during CBT is associated with a decrease in the activation of the brain's fear network to panic-related body symptoms.

NCT ID: NCT04460378 Recruiting - Agoraphobia Clinical Trials

Exposure Initializes Therapy - Treatment Of Homebound Patients Extended

ExITTOHoPE
Start date: January 1, 2018
Phase: N/A
Study type: Interventional

Cognitive behavioral treatment of homebound patients with severe agoraphobia.

NCT ID: NCT04293341 Recruiting - Clinical trials for Major Depressive Disorder

Comparing Individual Therapies for Veterans With Depression, PTSD, and Panic Disorder

Start date: October 1, 2020
Phase: N/A
Study type: Interventional

Cognitive behavioral therapy (CBT) is a brief, efficient, and effective treatment for individuals with depressive/anxiety disorders. However, CBT is largely underutilized within the Department of Veterans Affairs due to the cost and burden of trainings necessary to deliver all of the related disorder-specific treatments (DSTs). Transdiagnostic Behavior Therapy (TBT), in contrast, is specifically designed to address numerous distinct disorders within a single protocol in Veterans with depressive/anxiety disorders, including posttraumatic stress disorder. The proposed research seeks to evaluate the efficacy of TBT by assessing psychiatric symptomatology and related impairment outcomes in Veterans with depressive/anxiety disorders via a randomized controlled trial of TBT and existing DSTs in Veterans with major depressive disorder, posttraumatic stress disorder, and panic disorder. Assessments will be completed at pre-, mid-, and post-treatment, and at 6-month follow-up. Process variables also will be investigated.

NCT ID: NCT03925987 Completed - Clinical trials for Generalized Anxiety Disorder

Predicting Treatment Response to Exposure Therapy Using Carbon Dioxide

Start date: June 7, 2018
Phase: N/A
Study type: Interventional

Anxiety disorders affect over a quarter of the population, yet very little is known about the variables that predict treatment outcome. The planned study explores whether a patient's response to a physiological test involving inhalation of carbon dioxide predicts their response to exposure therapy.

NCT ID: NCT03899090 Active, not recruiting - Clinical trials for Major Depressive Disorder

Floatation-REST (Reduced Environmental Stimulation Therapy) for Anxiety and Depression

Start date: April 8, 2019
Phase: N/A
Study type: Interventional

This early-stage trial aims to examine the feasibility, tolerability, and safety of Floatation-REST (Reduced Environmental Stimulation Therapy) or an active comparison condition in 75 participants with clinical anxiety and depression.

NCT ID: NCT03885453 Recruiting - Depression Clinical Trials

Construction of a Questionnaire on Panic Disorder and Agoraphobia

Start date: March 2019
Phase:
Study type: Observational

For the first time panic disorder and agoraphobia are included as separate disorders in the DSM-5. Thus, agoraphobia no longer represents a subcategory of panic disorder. To diagnose both of the disorders, questionnaires are the method of choice. However, there are no measuring instruments available free of charge in German-speaking countries. In order to improve this situation, the Witten Panic Disorder Questionnaire (WPF) and the Witten Agoraphobia Questionnaire (WAF) are constructed in accordance with the DSM-5 criteria. Both measuring instruments are included as a part of a ten instrument battery. WAF and WPF will be delivered to a patient sample of patients with panic disorder and/or agoraphobia as well as depressed patients (discriminant validity). Factor analyzes and item analyses will be conducted.